American Society of Anesthesiologists

Figure 3. Responses to U-46619 in thromboxane A2(TXA2) receptor-expressing oocytes are mediated by inositol 1–4-5 trisphosphate (IP3). (A) Examples of responses induced by U-46619 (10 sup -6 M) in oocytes expressing TXA2receptors, in the absence and presence of intracellular IP3antagonist heparin (2 ng/nl, 50 nl). The charge movement in response to U-46619 is 5.8 micro C in the absence and 0.5 micro C in the presence of intracellular heparin. (B) Intracellular microinjection of the selective IP3antagonist heparin (2 ng/nl, 50 nl) inhibits U-46619 (10 sup -6 M)-induced ICl(Ca) to 10% of control (n = 5 in each group).

Figure 3. Responses to U-46619 in thromboxane A²(TXA²) receptor-expressing oocytes are mediated by inositol 1–4-5 trisphosphate (IP³). (A) Examples of responses induced by U-46619 (10 sup -6 M) in oocytes expressing TXA²receptors, in the absence and presence of intracellular IP³antagonist heparin (2 ng/nl, 50 nl). The charge movement in response to U-46619 is 5.8 micro C in the absence and 0.5 micro C in the presence of intracellular heparin. (B) Intracellular microinjection of the selective IP³antagonist heparin (2 ng/nl, 50 nl) inhibits U-46619 (10 sup -6 M)-induced I^Cl(Ca) to 10% of control (n = 5 in each group).

This Feature Is Available To Subscribers Only